<DOC>
	<DOCNO>NCT00775255</DOCNO>
	<brief_summary>To compare single-dose oral bioavailability clarithromycin 250-mg/5 mL powder oral suspension Ranbaxy Laboratories Abbott Laboratories ( Biaxin® ) follow administration 250 mg/5 mL dose healthy , adult , human , male subject fast condition .</brief_summary>
	<brief_title>Bioequivalence Study Clarithromycin 250 mg/5 mL Powder Oral Suspension Under Fasting Conditions</brief_title>
	<detailed_description>The study conduct open label , balance , randomise , two-treatment , two-period , two-sequence , single-dose , crossover , bioavailability study clarithromycin formulation compare clarithromycin 250 mg/5 mL powder oral suspension Ranbaxy Laboratories Biaxin® granules 250 mg/5 mL oral suspension ( contain clarithromycin 250 mg/5mL ) Abbott Laboratories healthy , adult , human , male subject fast condition . A single oral dose clarithromycin 250-mg/5 mL administer period study supervision train Medical Officer . During course study safety parameter assess vital sign , twelve-lead ECG , clinical examination , medical history , clinical laboratory safety test ( hematology , biochemical parameter urine analysis ) base line hematology biochemical parameter 24 hour post dose last period study . Twelve-lead ECG record 4 8 hour post-dose period . A Validated analytical method use analysis Clarithromycin human plasma . Pharmacokinetic statistical analysis perform conclude bioequivalence .</detailed_description>
	<mesh_term>Clarithromycin</mesh_term>
	<criteria>1 . Be age range 1845 year . 2 . Be neither overweight underweight his/her height per Life Insurance Corporation India height/weight chart nonmedical case . 3 . Have voluntarily give write informed consent participate study . 4 . Be normal health determine medical history physical examination subject perform within 14 day prior commencement study . 1 . History allergy clarithromycin , erythromycin related macrolides . 2 . History severe diarrhoea within 2 week precede Day 1 study . 3 . Any evidence organ dysfunction clinically significant deviation normal , physical clinical determination . 4 . Presence disease marker HIV 1 2 , Hepatitis B C viruses syphilis infection . 5 . Presence value significantly different normal reference range ( define Appendix 5 ) and/or judge clinically significant haemoglobin , total white blood cell count , differential WBC count platelet count . 6 . Positive urinary screen test drug abuse ( opiates cannabinoids ) 7 . Presence value significantly different normal reference range ( define Appendix 5 ) and/or judge clinically significant serum creatinine , blood urea nitrogen , serum aspartate aminotransferase ( AST ) , serum alanine aminotransferase ( ALT ) , serum alkaline phosphatase , serum bilirubin , plasma glucose serum cholesterol . 8 . Clinically abnormal chemical microscopic examination urine define presence RBC , WBC ( &gt; 4/HPF ) , glucose ( positive ) protein ( positive ) . 9 . Clinically abnormal ECG Chest Xray . 10 . QTc interval beyond normal limit . 11 . History serious gastrointestinal , hepatic , renal , cardiovascular , pulmonary , neurological haematological disease , diabetes glaucoma . 12 . History psychiatric illness might impair ability provide write informed consent . 13 . Regular smoker smoke 10 cigarette daily difficulty abstain smoke duration study period . 14 . History drug dependence excessive alcohol intake habitual basis 2 unit alcoholic beverage per day ( 1 unit equivalent half pint beer 1 glass wine 1 measure spirit ) difficulty abstain duration study period . 15 . Use enzyme modifying drug within 30 day prior Day 1 study . 16 . Participation clinical trial within 12 week precede Day 1 study . 17 . Subjects , completion study , would donate and/or lose 350 mL blood past 3 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Bioequiavelnce clarithromycin</keyword>
</DOC>